Cellectar Biosciences (CLRB) Earning Somewhat Positive Press Coverage, Analysis Shows
Media headlines about Cellectar Biosciences (NASDAQ:CLRB) have been trending somewhat positive on Sunday, according to Accern. The research firm scores the sentiment of media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cellectar Biosciences earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.5229447561939 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have effected Accern Sentiment Analysis’s analysis:
- Cellectar Biosciences, Inc. (CLRB) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
- CELLECTAR BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Unusual Activity Spotted in ProShares Short QQQ (PSQ) and Cellectar Biosciences Inc (CLRB) – FLBC News (flbcnews.com)
- Cellectar Biosciences (CLRB) Stock: This Is One For The Books! (cnafinance.com)
- Cellectar Biosciences Inc (NASDAQ:CLRB) Pops Higher on Strong Research Data – The Oracle Dispatch (oracledispatch.com)
Cellectar Biosciences (NASDAQ CLRB) opened at 1.65 on Friday. The company’s 50-day moving average is $1.56 and its 200-day moving average is $1.89. The stock’s market capitalization is $22.97 million. Cellectar Biosciences has a 12 month low of $1.12 and a 12 month high of $3.47.
Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.01. Equities analysts anticipate that Cellectar Biosciences will post ($0.92) earnings per share for the current year.
A number of research analysts recently commented on CLRB shares. ValuEngine downgraded shares of Cellectar Biosciences from a “sell” rating to a “strong sell” rating in a research report on Tuesday, May 23rd. Zacks Investment Research downgraded shares of Cellectar Biosciences from a “hold” rating to a “sell” rating in a research report on Friday, August 18th.
About Cellectar Biosciences
Cellectar Biosciences, Inc, formerly Novelos Therapeutics, Inc, is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform.
Receive News & Stock Ratings for Cellectar Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectar Biosciences Inc. and related stocks with our FREE daily email newsletter.